| Area of UK | Using liver fibrosis assessment in a pathway, n (%) | Using indirect serum fibrosis markers,an (%) | Using direct serum fibrosis markers,bn (%) | Using transient elastography,cn (%) |
|---|---|---|---|---|
| England n = 42 | 22 (52%) ( 39% ) | 27 (64%) (41% ) | 7 (17%) ( 13% ) | 17 (40%) ( 19% ) |
| Northern Ireland n = 5 | 0 (0%) (0%) | 1 (20%) ( 0% ) | 1 (20%) ( 0% ) | 1 (20%) ( 0% ) |
| Scotland n = 13 | 9 (69%) ( 67% ) | 10 (77%) ( 75% ) | 4 (31%) (50%) | 8 (62%) ( 58% ) |
| Wales n = 7 | 7 (100%) ( 100% ) | 7 (100%) ( 71% ) | 0 (0%) ( 29% ) | 5 (71%) ( 100% ) |
| UK total n = 67 | 38 (57%) ( 42% ) | 45 (67%) ( 44% ) | 12 (18%) ( 16% ) | 31 (46%) ( 25% ) |
The percentages highlighted in bold italics are the equivalent use of fibrosis tests reported in the 2020 survey5 aIncluded use of Fibrosis-4 (FIB-4) score, Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score and aspartate transaminase (AST):alanine transaminase (ALT) ratio (other options given). bAll but one response was for the enhanced liver fibrosis (ELF) blood test, single response hyaluronic acid. cAll using Fibroscan other than one response for shear wave ultrasound. n = number of commissioning bodies and health boards responding to survey